The 2 RCTs directly compared outcomes between 4-week INR recall intervals and 6-week79 recall intervals for patients meeting predefined criteria for stable VKA anticoagulation. No studies reported the impact of INR recall interval on quality of life. The EtD framework is shown online at https://dbep.gradepro. org/profile/87B38659-8876-FBC5-97CC-195E03A1F1FE. Benefits. For benefits, see the evidence profile in the EtD framework referenced at the end of the previous section, available online. Mortality was lower in the groups randomized to 6- to 12- week INR recall intervals, but the estimate is very imprecise, and CIs include both large increases and decreases in mortality (RR, 0.73 fewer to 140 more per 1000]; very low certainty). The 12-week INR recall interval was associated with a reduced risk for PE and DVT, but the estimates were based on only 1 event, and the CIs therefore include both important benefit and harm. The thromboembolic event rate from the other study was not used as it only included patients receiving anticoagulants for mechanical heart valves. There were also no differences between those using 6- to 12-week INR recall intervals and 4-week recall intervals for surrogate outcomes, including TTR and the number of extreme low/high INRs. Fewer patients using 6- to 12-week INR recall intervals had at least 1 dosing change during follow-up than those using 4-week recall [95% CI, 272 fewer to 67 fewer per 1000]; very low certainty). Harms and burden. Studies assessing major bleeding found no difference between those using 6- to 12-week INR recall intervals and those using 4-week recall intervals (RR, 1.05 [95% CI, per 1000] for average-bleeding-risk patients; low certainty). Other EtD criteria and considerations. The guideline panel agreed that 6- to 12-week INR recall intervals would probably result in moderate resources savings. 